[Correction of erectile dysfunction in patients undergoing radical prostatectomy]

Area of Science:

• Urology
• Oncology
• Sexual Medicine

Background:

• Radical prostatectomy (RPE) is a common treatment for localized prostate cancer.
• Erectile dysfunction (ED) is a frequent and significant complication following RPE, even with nerve-sparing techniques.
• ED severely impacts patients' quality of life and psychological well-being.

Discussion:

• A personalized, differentiated approach is crucial for managing post-RPE ED.
• "Patient expectation management" is a key factor for successful sexual rehabilitation.
• Conventional ED treatments require careful consideration of individual patient characteristics.

Key Insights:

• Phosphodiesterase type 5 inhibitors remain the first-line pharmacotherapy for erectile function recovery post-RPE.
• Combining phosphodiesterase type 5 inhibitors with other therapeutic modalities shows promising results for ED.
• Optimizing ED treatment strategies is essential for improving post-surgical outcomes.

Outlook:

• Further research into combination therapies for post-RPE ED is warranted.
• Developing tailored rehabilitation programs can enhance sexual function recovery.
• Improving patient-reported outcomes and quality of life remains a primary goal in prostate cancer survivorship.